Two-headed tetraphosphate cap analogs are inhibitors of the Dcp1/2 RNA decapping complex.

Abstract

Dcp1/2 is the major eukaryotic RNA decapping complex, comprised of the enzyme Dcp2 and activator Dcp1, which removes the 5′ m7G cap from mRNA, committing the transcript to degradation. Dcp1/2 activity is crucial for RNA quality control and turnover, and deregulation of these processes may lead to disease development. The molecular details of Dcp1/2 catalysis remain elusive, in part because both cap substrate (m7GpppN) and m7GDP product are bound by Dcp1/2 with weak (mM) affinity. In order to find inhibitors to use in elucidating the catalytic mechanism of Dcp2, we screened a small library of synthetic m7G nucleotides (cap analogs) bearing modifications in the oligophosphate chain. One of the most potent cap analogs, m7GpSpppSm7G, inhibited Dcp1/2 20 times more efficiently than m7GpppN or m7GDP. NMR experiments revealed that the compound interacts with specific surfaces of both regulatory and catalytic domains of Dcp2 with submillimolar affinities. Kinetics analysis revealed that m7GpSpppSm7G is a mixed inhibitor that competes for the Dcp2 active site with micromolar affinity. m7GpSpppSm7G-capped RNA undergoes rapid decapping, suggesting that the compound may act as a tightly bound cap mimic. Our identification of the first small molecule inhibitor of Dcp2 should be instrumental in future studies aimed at understanding the structural basis of RNA decapping and may provide insight toward the development of novel therapeutically relevant decapping inhibitors.